Advertisement
Screener

TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

TONIX PHARMACEUTICALS HOLDING CORP. Financing Cash Flow

TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) reported Financing Cash Flow of $53.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-10

  • TONIX PHARMACEUTICALS HOLDING CORP. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $33.51M, a 204.78% increase year-over-year.
  • TONIX PHARMACEUTICALS HOLDING CORP. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $20.20M, a 59.21% decline year-over-year.
  • TONIX PHARMACEUTICALS HOLDING CORP. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $59.14M, a 30.55% decline year-over-year.
  • TONIX PHARMACEUTICALS HOLDING CORP. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $94.86M, a 121.10% increase year-over-year.
  • TONIX PHARMACEUTICALS HOLDING CORP. net cash provided by (used in) financing activities for fiscal 2025 was $214.53M, a 59.06% increase from fiscal 2024.
  • TONIX PHARMACEUTICALS HOLDING CORP. net cash provided by (used in) financing activities for fiscal 2024 was $134.87M, a 269.34% increase from fiscal 2023.
  • TONIX PHARMACEUTICALS HOLDING CORP. net cash provided by (used in) financing activities for fiscal 2023 was $36.52M, a 58.43% decline from fiscal 2022.
  • TONIX PHARMACEUTICALS HOLDING CORP. net cash provided by (used in) financing activities for fiscal 2022 was $87.84M, a 58.66% decline from fiscal 2021.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 3 month as first filedNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 6 month as first filedNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 9 month as first filedNet Cash Provided by (Used in) Financing Activities 12 monthNet Cash Provided by (Used in) Financing Activities 43 monthNet Cash Provided by (Used in) Financing Activities 46 monthNet Cash Provided by (Used in) Financing Activities 55 monthNet Cash Provided by (Used in) Financing Activities 58 monthNet Cash Provided by (Used in) Financing Activities 61 monthNet Cash Provided by (Used in) Financing Activities 64 monthNet Cash Provided by (Used in) Financing Activities 67 monthNet Cash Provided by (Used in) Financing Activities 70 monthNet Cash Provided by (Used in) Financing Activities 73 monthNet Cash Provided by (Used in) Financing Activities 76 month
2026-06-30$33.51M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
$53.71M
10-Q · filed 2026-08-10
$112.85M
derived: sum of 3 quarters · filed 2026-08-10
$207.71M
derived: sum of 4 quarters · filed 2026-08-10
2026-03-31$20.20M
10-Q · filed 2026-05-11
$79.35M
derived: sum of 2 quarters · filed 2026-05-11
$174.21M
derived: sum of 3 quarters · filed 2026-05-11
$185.20M
derived: sum of 4 quarters · filed 2026-08-10
2025-12-31$59.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$154.00M
derived: sum of 2 quarters · filed 2026-03-12
$165.00M
derived: sum of 3 quarters · filed 2026-08-10
$214.53M
10-K · filed 2026-03-12
2025-09-30$94.86M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
$105.85M
derived: sum of 2 quarters · filed 2026-08-10
$155.39M
10-Q · filed 2025-11-10
$240.54M
derived: sum of 4 quarters · filed 2026-08-10
2025-06-30$10.99M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
$60.53M
10-Q · filed 2026-08-10
$145.68M
derived: sum of 3 quarters · filed 2026-08-10
$188.59M
derived: sum of 4 quarters · filed 2026-08-10
2025-03-31$49.53M
10-Q · filed 2026-05-11
$134.69M
derived: sum of 2 quarters · filed 2026-05-11
$177.59M
derived: sum of 3 quarters · filed 2026-05-11
$184.62M
derived: sum of 4 quarters · filed 2026-05-11
2024-12-31$85.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$128.06M
derived: sum of 2 quarters · filed 2026-03-12
$135.08M
derived: sum of 3 quarters · filed 2026-03-12
$134.87M
10-K · filed 2026-03-12
2024-09-30$42.91M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
$49.93M
derived: sum of 2 quarters · filed 2025-11-10
$49.72M
10-Q · filed 2025-11-10
$90.43M
derived: sum of 4 quarters · filed 2025-11-10
2024-06-30$7.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11
$6.81M
10-Q · filed 2025-08-11
$47.53M
derived: sum of 3 quarters · filed 2025-08-11
$53.80M
derived: sum of 4 quarters · filed 2025-08-11
2024-03-31-$212.00K
10-Q · filed 2025-05-12
$40.50M
derived: sum of 2 quarters · filed 2025-05-12
$46.78M
derived: sum of 3 quarters · filed 2025-05-12
$47.80M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31$40.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18
$46.99M
derived: sum of 2 quarters · filed 2025-03-18
$48.02M
derived: sum of 3 quarters · filed 2025-03-18
$36.52M
10-K · filed 2025-03-18
2023-09-30$6.27M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$7.30M
derived: sum of 2 quarters · filed 2024-11-12
-$4.20M
10-Q · filed 2024-11-12
$3.03M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$1.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-16
-$10.47M
10-Q · filed 2024-08-16
-$3.24M
derived: sum of 3 quarters · filed 2024-08-16
-$7.87M
derived: sum of 4 quarters · filed 2024-08-16
2023-03-31-$11.50M
10-Q · filed 2024-05-13
-$4.27M
derived: sum of 2 quarters · filed 2024-05-13
-$8.90M
derived: sum of 3 quarters · filed 2024-05-13
$63.28M
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31$7.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01
$2.60M
derived: sum of 2 quarters · filed 2024-04-01
$74.78M
derived: sum of 3 quarters · filed 2024-04-01
$87.84M
10-K · filed 2024-04-01
2022-09-30-$4.63M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$67.55M
derived: sum of 2 quarters · filed 2023-11-09
$80.61M
10-Q · filed 2023-11-09
$124.38M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30$72.18M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
$85.24M
10-Q · filed 2023-08-10
$129.01M
derived: sum of 3 quarters · filed 2023-08-10
$166.97M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31$13.06M
10-Q · filed 2023-05-08
$56.83M
derived: sum of 2 quarters · filed 2023-05-08
$94.79M
derived: sum of 3 quarters · filed 2023-05-08
$116.84M
derived: sum of 4 quarters · filed 2023-05-08
2021-12-31$43.77M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13
$81.73M
derived: sum of 2 quarters · filed 2023-03-13
$103.78M
derived: sum of 3 quarters · filed 2023-03-13
$212.49M
10-K · filed 2023-03-13
2021-09-30$37.96M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
$60.01M
derived: sum of 2 quarters · filed 2022-11-07
$168.72M
10-Q · filed 2022-11-07
$208.58M
derived: sum of 4 quarters · filed 2022-11-07
2021-06-30$22.05M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
$130.76M
10-Q · filed 2022-08-08
$170.62M
derived: sum of 3 quarters · filed 2022-08-08
$190.69M
derived: sum of 4 quarters · filed 2022-08-08
2021-03-31$108.71M
10-Q · filed 2022-05-09
$148.57M
derived: sum of 2 quarters · filed 2022-05-09
$168.64M
derived: sum of 3 quarters · filed 2022-05-09
$203.06M
derived: sum of 4 quarters · filed 2022-05-09
2020-12-31$39.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14
$59.93M
derived: sum of 2 quarters · filed 2022-03-14
$94.35M
derived: sum of 3 quarters · filed 2022-03-14
$123.11M
10-K · filed 2022-03-14
2020-09-30$20.07M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
$54.49M
derived: sum of 2 quarters · filed 2021-11-08
$83.25M
10-Q · filed 2021-11-08
$91.16M
derived: sum of 4 quarters · filed 2021-11-08
2020-06-30$34.42M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09
$63.18M
10-Q · filed 2021-08-09
$71.09M
derived: sum of 3 quarters · filed 2021-08-09
$75.61M
derived: sum of 4 quarters · filed 2021-08-09
2020-03-31$28.76M
10-Q · filed 2021-05-10
$36.67M
derived: sum of 2 quarters · filed 2021-05-10
$41.19M
derived: sum of 3 quarters · filed 2021-05-10
$41.60M
derived: sum of 4 quarters · filed 2021-05-10
2019-12-31$7.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15
$12.43M
derived: sum of 2 quarters · filed 2021-03-15
$12.85M
derived: sum of 3 quarters · filed 2021-03-15
$12.92M
10-K · filed 2021-03-15
2019-09-30$4.51M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
$4.93M
derived: sum of 2 quarters · filed 2020-11-09
$5.00M
10-Q · filed 2020-11-09
$4.97M
10-Q · filed 2019-11-08
$22.19M
derived: sum of 4 quarters · filed 2020-11-09
2019-06-30$417.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
$490.00K
10-Q · filed 2020-08-10
$17.68M
derived: sum of 3 quarters · filed 2020-08-10
$20.57M
derived: sum of 4 quarters · filed 2020-08-10
2019-03-31$73.00K
10-Q · filed 2020-05-12
$70.00K
10-Q · filed 2019-05-13
$17.26M
derived: sum of 2 quarters · filed 2020-05-12
$20.15M
derived: sum of 3 quarters · filed 2020-05-12
$23.08M
derived: sum of 4 quarters · filed 2020-05-12
2018-12-31$17.19M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-24
$20.08M
derived: sum of 2 quarters · filed 2020-03-24
$23.01M
derived: sum of 3 quarters · filed 2020-03-24
$23.54M
10-K · filed 2020-03-24
2018-09-30$2.89M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08
$5.82M
derived: sum of 2 quarters · filed 2019-11-08
$6.35M
10-Q · filed 2019-11-08
$7.47M
derived: sum of 4 quarters · filed 2019-11-08
2018-06-30$2.93M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12
$3.46M
10-Q · filed 2019-08-12
$4.58M
derived: sum of 3 quarters · filed 2019-08-12
$4.58M
derived: sum of 4 quarters · filed 2019-08-12
2018-03-31$532.00K
10-Q · filed 2019-05-13
$1.65M
derived: sum of 2 quarters · filed 2019-05-13
$1.65M
derived: sum of 3 quarters · filed 2019-05-13
$17.95M
derived: sum of 4 quarters · filed 2019-05-13
2017-12-31$1.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18
$1.12M
derived: sum of 2 quarters · filed 2019-03-18
$17.42M
derived: sum of 3 quarters · filed 2019-03-18
$18.52M
10-K · filed 2019-03-18
2017-09-30$1.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09
$16.30M
derived: sum of 2 quarters · filed 2018-11-09
$17.40M
10-Q · filed 2018-11-09
$22.26M
derived: sum of 4 quarters · filed 2018-11-09
2017-06-30$16.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13
$17.40M
10-Q · filed 2018-08-13
$22.26M
derived: sum of 3 quarters · filed 2018-08-13
2017-03-31$1.10M
10-Q · filed 2018-05-11
$5.96M
derived: sum of 2 quarters · filed 2018-05-11
2016-12-31$4.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09
$20.50M
10-K · filed 2018-03-09
2016-09-30$15.64M
10-Q · filed 2017-11-06
2013-09-30$10.22M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13
$10.63M
derived: sum of 2 quarters · filed 2013-11-13
$10.63M
10-Q · filed 2013-11-13
$13.88M
derived: sum of 4 quarters · filed 2013-11-22
$22.76M
10-Q · filed 2013-11-13
2013-06-30$405.75K
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14
$405.75K
10-Q · filed 2013-08-14
$3.66M
derived: sum of 3 quarters · filed 2013-11-22
$3.66M
derived: sum of 4 quarters · filed 2013-11-22
$12.53M
10-Q · filed 2013-08-14
2013-03-31$0.00
10-Q · filed 2013-05-07
$3.25M
derived: sum of 2 quarters · filed 2013-11-22
$3.25M
derived: sum of 3 quarters · filed 2013-11-22
$3.25M
derived: sum of 4 quarters · filed 2013-11-22
$12.13M
10-Q · filed 2013-05-07
2012-12-31$3.25M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2013-11-22
$3.25M
derived: sum of 2 quarters · filed 2013-11-22
$3.25M
derived: sum of 3 quarters · filed 2013-11-22
$7.49M
10-K/A · filed 2013-11-22
$12.13M
10-K/A · filed 2013-11-22
2012-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13
-$1.00
derived: sum of 2 quarters · filed 2013-11-13
$4.24M
10-Q · filed 2013-11-13
$5.74M
derived: sum of 4 quarters · filed 2013-11-22
$8.87M
10-Q · filed 2012-11-14
2012-06-30-$1.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14
$4.24M
10-Q · filed 2013-08-14
$5.74M
derived: sum of 3 quarters · filed 2013-11-22
$6.28M
derived: sum of 4 quarters · filed 2013-11-22
$8.87M
10-Q · filed 2012-08-13
2012-03-31$4.24M
10-Q · filed 2013-05-07
$5.74M
derived: sum of 2 quarters · filed 2013-11-22
$6.28M
derived: sum of 3 quarters · filed 2013-11-22
$6.55M
derived: sum of 4 quarters · filed 2013-11-22
$8.87M
10-Q · filed 2012-05-15
2011-12-31$1.50M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2013-11-22
$2.04M
derived: sum of 2 quarters · filed 2013-11-22
$2.31M
derived: sum of 3 quarters · filed 2013-11-22
$2.61M
10-K/A · filed 2013-11-22
$4.64M
10-K · filed 2012-03-30
2011-09-30$544.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-14
$809.00K
derived: sum of 2 quarters · filed 2012-11-14
$1.11M
10-Q · filed 2012-11-14
$0.00
10-Q · filed 2011-10-07
$2.50M
derived: sum of 4 quarters · filed 2012-11-14
$75.00K
10-Q · filed 2011-10-07
2011-06-30$265.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-13
$568.00K
10-Q · filed 2012-08-13
$0.00
10-Q · filed 2011-08-15
$1.96M
derived: sum of 3 quarters · filed 2012-08-13
$1.96M
derived: sum of 4 quarters · filed 2012-08-13
$75.00K
10-Q · filed 2011-08-15
2011-03-31$303.00K
10-Q · filed 2012-05-15
$1.69M
derived: sum of 2 quarters · filed 2012-05-15
$1.70M
derived: sum of 3 quarters · filed 2012-05-15
2010-12-31$1.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-30
$1.39M
derived: sum of 2 quarters · filed 2012-03-30
$1.39M
10-K · filed 2012-03-30
2010-09-30$2.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-07
$2.00K
10-Q · filed 2011-10-07
2010-06-30$0.00
10-Q · filed 2011-08-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Minerva Neurosciences, Inc. (NERV)United States$0.165B-0.66
ADC Therapeutics SA (ADCT)$0.163B-1.39
LIFECORE BIOMEDICAL, INC. DE (LFCR)United States$0.163B-8.50
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
Annexon, Inc. (ANNX)United States$0.147B-4.22
PepGen Inc. (PEPG)United States$0.186B-1.73
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91